These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
73 related articles for article (PubMed ID: 19945666)
1. [Fusion genes and prostate cancer. From discovery to prognosis and therapeutic perspectives]. Beuzeboc P; Soulié M; Richaud P; Salomon L; Staerman F; Peyromaure M; Mongiat-Artus P; Cornud F; Paparel P; Davin JL; Molinié V Prog Urol; 2009 Dec; 19(11):819-24. PubMed ID: 19945666 [TBL] [Abstract][Full Text] [Related]
2. [Molecular biology and prostate cancer: evolution or revolution?]. Molinié V; Beuzeboc P; Mahjoub WK; Ann Pathol; 2008 Oct; 28(5):354-62. PubMed ID: 19068390 [TBL] [Abstract][Full Text] [Related]
3. Clinical implications of TMPRSS2-ERG gene fusion expression in patients with prostate cancer treated with radical prostatectomy. Rubio-Briones J; Fernández-Serra A; Calatrava A; García-Casado Z; Rubio L; Bonillo MA; Iborra I; Solsona E; López-Guerrero JA J Urol; 2010 May; 183(5):2054-61. PubMed ID: 20303538 [TBL] [Abstract][Full Text] [Related]
4. TMPRSS2:ERG gene fusion associated with lethal prostate cancer in a watchful waiting cohort. Demichelis F; Fall K; Perner S; Andrén O; Schmidt F; Setlur SR; Hoshida Y; Mosquera JM; Pawitan Y; Lee C; Adami HO; Mucci LA; Kantoff PW; Andersson SO; Chinnaiyan AM; Johansson JE; Rubin MA Oncogene; 2007 Jul; 26(31):4596-9. PubMed ID: 17237811 [TBL] [Abstract][Full Text] [Related]
5. Molecular genetic analyses of the TMPRSS2-ERG and TMPRSS2-ETV1 gene fusions in 50 cases of prostate cancer. Winnes M; Lissbrant E; Damber JE; Stenman G Oncol Rep; 2007 May; 17(5):1033-6. PubMed ID: 17390040 [TBL] [Abstract][Full Text] [Related]
6. [Frequent gene fusion in prostate cancer: clinical applications in diagnosis, prognosis and therapy]. Schmidt F; Scheble V; Mertz K; Perner S; Rubin MA Dtsch Med Wochenschr; 2009 Jul; 134(28-29):1483-6. PubMed ID: 19572250 [TBL] [Abstract][Full Text] [Related]
7. Expression of variant TMPRSS2/ERG fusion messenger RNAs is associated with aggressive prostate cancer. Wang J; Cai Y; Ren C; Ittmann M Cancer Res; 2006 Sep; 66(17):8347-51. PubMed ID: 16951141 [TBL] [Abstract][Full Text] [Related]
8. The discovery of common recurrent transmembrane protease serine 2 (TMPRSS2)-erythroblastosis virus E26 transforming sequence (ETS) gene fusions in prostate cancer: significance and clinical implications. Shah RB; Chinnaiyan AM Adv Anat Pathol; 2009 May; 16(3):145-53. PubMed ID: 19395877 [TBL] [Abstract][Full Text] [Related]
9. Overexpression of prostate-specific TMPRSS2(exon 0)-ERG fusion transcripts corresponds with favorable prognosis of prostate cancer. Hermans KG; Boormans JL; Gasi D; van Leenders GJ; Jenster G; Verhagen PC; Trapman J Clin Cancer Res; 2009 Oct; 15(20):6398-403. PubMed ID: 19825963 [TBL] [Abstract][Full Text] [Related]